If you didn't find what you were looking for, try a new search!
I last reviewed Danaher (DHR) in this October 21, 2022 post at which time I held 285 DHR shares in a 'Core' account in the FFJ Portfolio. In a brief January 6, 2023 post, I disclose the purchase of an additional 50 shares @ ~$246.18/share thereby increasing my exposure to 335 shares. I subsequently acquired: [...]
Nike (NKE) shareholders have experienced sub-par total investment returns over the past 5 years (an average annual total return of ~7.3% versus ~11.4% for the S&P 500 when dividends are reinvested). NKE's average annual total return drops to (18.42%) versus ~2% for the S&P 500 if we change the timeframe to 2 years. Change the [...]
I consider low-risk Paychex (PAYX) to currently be attractively valued. I last reviewed this holding in my March 30, 2023 post at which time Q3 and YTD2023 results had just been released. With the release of its Q4 and FY2023 results and FY2024 outlook, I briefly revisit this holding. Business Overview Although I provide a [...]
In January, my Scotiabank (BNS) Is A Terrible Long-Term Investment guest post was published at Dividend Power. My recent TD Bank (TD) guest post is now accessible at Dividend Power. In my opinion, TD is far more appealing than BNS from a total long-term investment return perspective. Furthermore, I deem TD's credit risk to be [...]
Fortunately for Rollins (ROL), pests are indifferent to economic conditions. It generates ~80% recurring revenue and boats 20+ years of revenue growth. I last reviewed this holding in my November 19, 2022 post. With the release of FY2022 results following the February 15 market close, I revisit it to determine whether I should acquire additional [...]
I would have preferred to wait for the release of Stryker's (SYK) FY2022 Form 10-K. However, I have sufficient information in its January 31, 2023 Q4 2022 Form 8-K and the Form 10-Ks from prior years by which to make an investment decision. In this post, I point out several observations that convinced me SYK [...]
I last reviewed Moody's Corporation (MCO) in this July 26, 2022 post at which time MCO had just released Q2 and YTD2022 results. Based on this analysis of MCO's Q4 and FY2022 results and FY2023 outlook released on January 31, 2023, I am not adding to my exposure because the current valuation is not justified. [...]
I last reviewed CVX in my August 18, 2022 guest post at Dividend Power at which time I concluded that the oil and gas demise was overblown. Following the January 27 release of Chevron's (CVX) exceptional FY2022 results, there appears to be a bit too much euphoria. This certainly was evident when CVX announced its [...]
I last reviewed Raytheon Technologies (RTX) in this July 27, 2022 post. With the January 24, 2022 release of Q4 and FY2022 results and FY2023 outlook, I revisit it to determine whether I should add to my exposure. Business Overview Investors unfamiliar with RTX are encouraged to review the company's website and Part 1 Item [...]
In my most recent guest post contribution at Portfolio Insight, I share CME Group (CME) as my top dividend stock pick for 2023; my November 14, 2022 CME Group Is Low-Risk and Attractively Valued post goes into more detail as to why I invest in this company. The request was for a very brief write-up [...]